Wang Cen, Yu Ye, Zhu Wengen, Yu Jianhua, Lip Gregory Y H, Hong Kui
Department of Cardiovascular Medicine, the Second Affiliated Hospital of Nanchang University, Jiangxi, China.
University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, United Kingdom.
Oncotarget. 2017 Aug 3;8(65):109703-109711. doi: 10.18632/oncotarget.19858. eCollection 2017 Dec 12.
The HAS-BLED and ORBIT scores have been proposed to assess bleeding risk in anticoagulated atrial fibrillation patients. We performed a systematic review and meta-analysis to compare the predictive ability by using these two scores.
We searched the Cochrane Library, Elsevier and PubMed databases for related studies. Statistical analysis was performed with Revman 5.3 Manager software. We chose the C-statistic to reflect the diagnostic value.
In our seven selected studies, the pooled C- statistic of continuous variables for major bleeding was 0.65 (0.60,0.69) for ORBIT and 0.63 (0.60,0.66) for HAS-BLED. Compared with HAS-BLED, more anticoagulated AF patients (88.45% versus 32.59%) and major bleeding events (75.57% versus 25.57%) were categorized as low risk. The ORBIT score had a 1.21, 1.73 and 1.44-fold elevated risk of major bleeding in the low, intermediate and high risk strata respectively. Calibration analysis demonstrated that the ORBIT score under-predicted major bleeding in the low, intermediate, and high risk stratifications, where a odds ratio of 0.64 (0.37-1.10), 0.63 (0.38-1.05) and 0.64 (0.38-1.06), respectively.
Compared with HAS-BLED , the ORBIT score does not perform better in predicting major bleeding events in anticoagulated atrial fibrillation patients. More anticoagulated AF patients and major bleeding events were categorized as low risk when using ORBIT.
HAS - BLED和ORBIT评分已被用于评估抗凝治疗的房颤患者的出血风险。我们进行了一项系统评价和荟萃分析,以比较这两种评分的预测能力。
我们检索了Cochrane图书馆、爱思唯尔和PubMed数据库中的相关研究。使用Revman 5.3 Manager软件进行统计分析。我们选择C统计量来反映诊断价值。
在我们选择的七项研究中,ORBIT评分中主要出血连续变量的合并C统计量为0.65(0.60,0.69),HAS - BLED评分为0.63(0.60,0.66)。与HAS - BLED相比,更多接受抗凝治疗的房颤患者(88.45%对32.59%)和主要出血事件(75.57%对25.57%)被归类为低风险。ORBIT评分在低、中、高风险分层中发生主要出血的风险分别升高了1.21倍、1.73倍和1.44倍。校准分析表明,ORBIT评分在低、中、高风险分层中对主要出血的预测不足,其比值比分别为0.64(0.37 - 1.10)、0.63(0.38 - 1.05)和0.64(0.38 - 1.06)。
与HAS - BLED相比,ORBIT评分在预测抗凝治疗的房颤患者主要出血事件方面表现并不更好。使用ORBIT时,更多接受抗凝治疗的房颤患者和主要出血事件被归类为低风险。